APA (7th ed.) Citation

Z, A., H, B., O, A., G, M., SB, S., S, E., . . . M, D. (2022). Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS medicine, 19(1), e1003865. https://doi.org/10.1371/journal.pmed.1003865

Chicago Style (17th ed.) Citation

Z, Anywaine, et al. "Safety and Immunogenicity of 2-dose Heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccination in Children and Adolescents in Africa: A Randomised, Placebo-controlled, Multicentre Phase II Clinical Trial." PLoS Medicine 19, no. 1 (2022): e1003865. https://doi.org/10.1371/journal.pmed.1003865.

MLA (9th ed.) Citation

Z, Anywaine, et al. "Safety and Immunogenicity of 2-dose Heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccination in Children and Adolescents in Africa: A Randomised, Placebo-controlled, Multicentre Phase II Clinical Trial." PLoS Medicine, vol. 19, no. 1, 2022, p. e1003865, https://doi.org/10.1371/journal.pmed.1003865.